Global report warns of escalating cancer rate

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

A coalition of international cancer experts is warning that the global cancer burden will double over the next two decades with an increasing concentration of cases in low-income and middle-income countries.

A coalition of international cancer experts is warning that the global cancer burden will double over the next two decades with an increasing concentration of cases in low-income and middle-income countries.

The Cancer Treatment Informal Working Group (CanTreat International) released a new report, "The Hidden Epidemic: Women's Cancers in Low- and Middle-Income Countries," at ECCO/ESMO 2009 (abstract 31).

More than half of the 12.4 million estimated new cases of cancer, and two-thirds of the estimated 7.6 million cancer deaths in 2008, occurred in developing countries, where cancer kills more people each year than AIDS, tuberculosis, and malaria, according to the CanTreat International report.

The document also highlights growing incidence of breast cancer and cervical cancer in middle-income Eastern Europe and Russia. Copies of the report are available at www.axios-group.com.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content